AI assistant
BIO-TECHNE Corp — Director's Dealing 2020
Jul 13, 2020
30718_dirs_2020-07-13_8e5db701-081c-4937-bfaf-0c808433040d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2020-07-09
Reporting Person: Furlow Brenda S. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-07-09 | Common Stock | M | 9079.00 | $108.49 | Acquired | 13390.00 | Direct |
| 2020-07-09 | Common Stock | S | 440.00 | $270.9659 | Disposed | 12950.00 | Direct |
| 2020-07-09 | Common Stock | S | 505.00 | $272.4778 | Disposed | 12445.00 | Direct |
| 2020-07-09 | Common Stock | S | 2042.00 | $273.3317 | Disposed | 10403.00 | Direct |
| 2020-07-09 | Common Stock | S | 918.00 | $274.8048 | Disposed | 9485.00 | Direct |
| 2020-07-09 | Common Stock | S | 400.00 | $276.025 | Disposed | 9085.00 | Direct |
| 2020-07-09 | Common Stock | S | 1954.00 | $277.2836 | Disposed | 7131.00 | Direct |
| 2020-07-09 | Common Stock | S | 2746.00 | $278.061 | Disposed | 4385.00 | Direct |
| 2020-07-09 | Common Stock | S | 74.00 | $278.84 | Disposed | 4311.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-07-09 | Stock Option (Right to Buy) | $108.49 | M | 9079.00 | Disposed | 2022-08-07 | Common Stock (9079.00) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Restricted Stock Units | $ | Common Stock (1724.00) | 1724.00 | Direct | |
| Restricted Stock Units | $ | Common Stock (1969.00) | 1969.00 | Direct | |
| Restricted Stock Units | $ | Common Stock (1374.00) | 1374.00 | Direct | |
| Stock Option (Right to Buy) | $106.59 | 2023-08-18 | Common Stock (10857.00) | 10857.00 | Direct |
| Stock Options (Right to Buy) | $190.41 | 2026-08-07 | Common Stock (13290.00) | 13290.00 | Direct |
| Stock Options (Right to Buy) | $177.32 | 2025-08-08 | Common Stock (9786.00) | 9786.00 | Direct |
| Stock Options (Right to buy) | $177.32 | 2025-08-08 | Common Stock (7339.00) | 7339.00 | Direct |
| Stock Options (Right to Buy) | $125.05 | 2024-08-09 | Common Stock (12670.00) | 12670.00 | Direct |
| Stock Options (Right to buy) | $125.05 | 2024-08-09 | Common Stock (9503.00) | 9503.00 | Direct |
| Stock Options (Right to Buy) | $106.59 | 2023-08-18 | Common Stock (14476.00) | 14476.00 | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.6400 to $271.5000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.8500 to $272.8300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8500 to $273.7900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.3100 to $275.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.4000 to $276.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.6500 to $277.6200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.7700 to $278.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: Vests 2,500 share(s) on 07-Aug-2016, 2,500 share(s) on 07-Aug-2017, 2,500 share(s) on 07-Aug-2018, 1,579 share(s) on 07-Aug-2019
F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F11: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F12: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)
F13: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14: Fully exercisable
F15: Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
F16: Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
F17: Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
F18: Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.